Cambridge Cognition Holdings plc (LON:COG) is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition.
DRUG Development
DIGITAL Health
COGNITIVE Research
Maximise The Chances Of Success In Clinical Trials
Industry-leading and regulatory-accepted digital products to optimise and accelerate safe, effective and efficient drug development.
- Enrich clinical trial recruitment
- Develop new treatments
- Improve patient outcomes
Assess And Improve Brain Health And Mental Wellbeing
Medical devices and digital health technology to collect real world outcomes data, identify patients, detect impairments early, and track wellbeing over time.
- Alzheimer’s screening
- Cognitive health assessments
- Mental health at work
The Gold Standard In Cognitive Assessment
The world’s most recognised digital cognitive testing platform for all areas of brain research providing sensitive assessment of cognitive domains in-person and online.
- CANTAB cognitive assessments
- Training and support
- Neurocience consultancy